primary: BP control in subjects with poorly controlled hypertension at baseline (OR = 1.03; 95% CI 0.79−1.35; p > 0.05); measurement of PTH during the study (46.9% vs. 16.1%; p < 0.001); secondary: number of classes of antihypertensive drugs being prescribed (p = 0.02); change in HRQoL (52.0 ± 10.6 vs. 52.1 ± 9.6: p > 0.05); mortality (RR = 1.40; 95% CI 0.99−1.99; p = 0.06); medication adherence (6.8 ± 1.2 vs. 6.7 ± 1.2; p > 0.05). The gene discussed is PTH; the disease is Hypertension.